Suppr超能文献

提出一个临床算法,以在资源有限的情况下更好地诊断低磷酸酯酶症。

Proposing a clinical algorithm for better diagnosis of hypophosphatasia in resource-limiting situations.

机构信息

Division of Endocrinology and Centre for Research in Anabolic Skeletal Targets in Health and Illness (ASTHI), CSIR-Central Drug Research Institute, Lucknow, India.

Academy of Scientific and Innovative Research, Ghaziabad, 201002, India.

出版信息

Osteoporos Int. 2022 Dec;33(12):2479-2493. doi: 10.1007/s00198-022-06480-1. Epub 2022 Jul 1.

Abstract

Early diagnosis of hypophosphatasia (HPP) is challenging. Here, we propose to broaden the diagnostic criteria of HPP by reviewing published data on BMD and fractures in HPP patients. Non-osteoporotic fractures and higher than normal lumbar BMD were recurrent in HPP patients and could be included as diagnostic criteria. HPP is a genetic disorder caused by autosomal recessive or dominant loss-of-function mutations in the ALPL gene that encodes for tissue-nonspecific alkaline phosphatase (TNSALP). Expressive genetic heterogeneity and varying severity of TNSALP deficiency lead to a wide-ranging presentation of skeletal diseases at different ages that coupled with HPP's rarity and limitation of biochemical and mutational studies present serious hurdles to early diagnosis and management of HPP. To widen the scope of HPP diagnosis, we assessed the possibility of areal bone mineral density (BMD) as an additional clinical feature of this disease. PubMed, Web of Science, and ScienceDirect were searched with the following keywords: ("Hypophosphatasia OR HPP") AND ("Bone Mineral Density OR BMD") AND "Human". Studies and case reports of subjects with age ≥ 18 years and having BMD data were included. We pooled data from 25 publications comprising 356 subjects (90 males, 266 females). Only four studies had a control group. Biochemical hallmarks, pyridoxal 5'-phosphate (PLP) and phosphoethanolamine (PEA), were reported in fifteen and six studies, respectively. Twenty studies reported genetic data, nineteen studies reported non-vertebral fractures, all studies reported lumbar spine (LS) BMD, and nineteen reported non-vertebral BMD. Higher than normal and normal BMD at LS were reported in three and two studies, respectively. There was marked heterogeneity in BMD at the non-vertebral sites. Higher than normal or normal LS BMD in an adult with minimal or insufficient fractures, pseudofractures, non-healing fractures, fragility fractures, and stress fractures may be included in the diagnostic protocol of HPP. However, genetic testing is recommended for a definitive diagnosis.

摘要

成骨不全症(HPP)的早期诊断具有挑战性。在这里,我们通过回顾 HPP 患者的骨密度(BMD)和骨折发表数据,提出拓宽 HPP 诊断标准的建议。非骨质疏松性骨折和高于正常的腰椎 BMD 在 HPP 患者中经常发生,可作为诊断标准。HPP 是一种由常染色体隐性或显性失活突变引起的遗传性疾病,该基因编码组织非特异性碱性磷酸酶(TNSALP)。表达遗传异质性和 TNSALP 缺乏的严重程度不同,导致不同年龄的骨骼疾病表现广泛,再加上 HPP 的罕见性和生化及突变研究的局限性,对 HPP 的早期诊断和管理构成了严重障碍。为了扩大 HPP 的诊断范围,我们评估了 BMD 作为该疾病的另一个临床特征的可能性。使用以下关键词在 PubMed、Web of Science 和 ScienceDirect 上进行了搜索:("Hypophosphatasia OR HPP") AND ("Bone Mineral Density OR BMD") AND "Human"。纳入了年龄≥18 岁且具有 BMD 数据的研究和病例报告。我们汇总了 25 篇文献中的数据,这些文献共包含 356 名受试者(90 名男性,266 名女性)。仅有 4 项研究有对照组。15 项研究报告了生化标志物吡哆醛 5'-磷酸(PLP),6 项研究报告了磷酸乙醇胺(PEA)。20 项研究报告了遗传数据,19 项研究报告了非椎体骨折,所有研究均报告了腰椎(LS)BMD,19 项研究报告了非椎体 BMD。3 项研究报告 LS 的 BMD 高于正常或正常,2 项研究报告 LS 的 BMD 正常。非椎体部位的 BMD 存在显著异质性。在无明显骨折、假性骨折、骨折不愈合、脆性骨折和应力性骨折的成年患者中,LS 高于正常或正常 BMD 可能被纳入 HPP 的诊断方案中。但是,建议进行基因检测以明确诊断。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验